ABEO Abeona Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ABEO

Price (delayed)

$7.01

Market cap

$399.54M

P/E Ratio

5.61

Dividend/share

N/A

EPS

$1.25

Enterprise value

$361.33M

?
Relative Growth: Rel. Growth: 46
Relative Strength: Rel. Strength: 80
Relative Valuation: Rel. Valuation: 92
Relative Profitability: Rel. Profitability: 87

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis ...

Highlights
The revenue has soared by 150% since the previous quarter
The company's gross profit has surged by 140% QoQ
The company's quick ratio rose by 18% YoY but it fell by 16% QoQ
The price to earnings (P/E) is 40% higher than the last 4 quarters average of 4.0
Abeona Therapeutics's equity has decreased by 9% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://abeonatherapeutics.com
Peers: MRK

Key stats

What are the main financial stats of ABEO

ABEO stock price

How has the Abeona Therapeutics stock price performed over time
Intraday
0.43%
1 week
11.09%
1 month
26.76%
1 year
22.13%
YTD
33.02%
QTD
13.43%

Financial performance

How have Abeona Therapeutics's revenue and profit performed over time
Revenue
$14.54M
Gross profit
$10.31M
Operating income
-$90.86M
Net income
$66.14M
Gross margin
70.9%
Net margin
454.9%
The revenue has soared by 150% since the previous quarter
The company's gross profit has surged by 140% QoQ
Abeona Therapeutics's net margin has shrunk by 63% QoQ
ABEO's operating margin has soared by 58% QoQ

Price vs fundamentals

How does ABEO's price correlate with its fundamentals

Growth

What is Abeona Therapeutics's growth rate over time

Valuation

What is Abeona Therapeutics stock price valuation
P/E
5.61
P/B
2.76
P/S
27.3
EV/EBIT
5.18
EV/EBITDA
4.92
EV/Sales
24.85
The price to earnings (P/E) is 40% higher than the last 4 quarters average of 4.0
ABEO's EPS is down by 7% since the previous quarter
The price to book (P/B) is 62% higher than the last 4 quarters average of 1.7 but 16% lower than the 5-year quarterly average of 3.3
Abeona Therapeutics's equity has decreased by 9% QoQ
The revenue has soared by 150% since the previous quarter
ABEO's P/S is 93% below its last 4 quarters average of 381.8

Efficiency

How efficient is Abeona Therapeutics business performance
The company's return on assets has surged by 177% YoY but it fell by 18% QoQ
Abeona Therapeutics's return on equity has surged by 148% YoY but it has decreased by 22% QoQ
ABEO's ROS has dropped by 63% since the previous quarter
The company's return on invested capital fell by 15% QoQ

Dividends

What is ABEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABEO.

Financial health

How did Abeona Therapeutics financials performed over time
The company's total assets has surged by 100% YoY but it fell by 10% QoQ
The current ratio is up by 20% year-on-year but it has declined by 15% since the previous quarter
Abeona Therapeutics's debt is 84% lower than its equity
Abeona Therapeutics's debt to equity has shrunk by 72% YoY
Abeona Therapeutics's equity has decreased by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.